Drug pricing and healthcare costs surface every Congressional cycle as one of the top three issues voters cite. The 119th Congress has multiple bills addressing Medicare drug negotiation expansion, ACA marketplace subsidies, hospital pricing transparency, and PBM reform.
This page tracks them all. Every active bill, recent vote, and committee action on the cost of American healthcare.
On the Amendment S.Amdt. 1116 to H.R. 2 (Medicare Access and CHIP Reauthorization Act of 2015)
2015-04-14
Senate · Amendment Rejected (42-58)
On the Amendment S.Amdt. 1118 to H.R. 2 (Medicare Access and CHIP Reauthorization Act of 2015)
2015-04-14
Senate · Amendment Rejected (11-89)
Coverage
Frequently Asked
What is Medicare drug price negotiation?
A 2022 law authorized Medicare to negotiate prices on a small list of drugs. Multiple 119th Congress bills propose either to expand the list or to repeal the authority entirely.
Are ACA subsidies expiring?
Enhanced ACA marketplace subsidies are scheduled to lapse without Congressional action. Bills extending them are tracked here, alongside the votes if and when they come.
What is PBM reform?
Pharmacy Benefit Manager reform bills target the middlemen between drugmakers and insurers. Multiple bipartisan bills exist; passage prospects vary by chamber.
